Taysha Gene Therapies (TSHA) EBITDA Margin (2023 - 2025)
Taysha Gene Therapies' (TSHA) quarterly EBITDA Margin came in at 2334.98% in Q4 2025, down 134923.0% year-on-year from N/an in Q4 2024, and down 73.34% quarter-over-quarter from 1347.08% in Q2 2025.
Taysha Gene Therapies (TSHA) EBITDA Margin (2023 - 2025) Analysis & Trends
Taysha Gene Therapies has disclosed EBITDA Margin across 3 years of filings, most recently posting 2334.98% for Q4 2025.
- EBITDA Margin for Q4 2025 came in at 2334.98%, down 134923.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 4145.18% (down 291941.0% YoY), and the FY2025 annual result was 2009.05%, down 91150.0% from the prior year.
- EBITDA Margin came in at 2334.98% for Q4 2025 at Taysha Gene Therapies, down from 1347.08% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 342.39% in Q3 2023 to a low of 2334.98% in Q4 2025.
- The 3-year median for EBITDA Margin is 976.37% (2023), against an average of 1072.44%.
- Peak annual rise in EBITDA Margin reached 56830 bps in 2025, while the deepest fall reached 134923 bps in 2025.
- Taysha Gene Therapies' EBITDA Margin stood at 450.78% in 2023, then sank by 119 bps to 985.76% in 2024, then tumbled by 137 bps to 2334.98% in 2025.
- The last three EBITDA Margin figures came in at 2334.98% (Q4 2025), 1347.08% (Q2 2025), and 930.54% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Taysha Gene Therapies | 2.36 Bn | 2.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,334.98% |
| Jun 30, 2025 | -1,347.08% |
| Mar 31, 2025 | -930.54% |
| Dec 31, 2024 | -985.76% |
| Sep 30, 2024 | -1,448.43% |
| Jun 30, 2024 | -1,915.38% |
| Mar 31, 2024 | -713.28% |
| Dec 31, 2023 | -450.78% |
| Sep 30, 2023 | -342.39% |
| Jun 30, 2023 | -976.37% |
| Mar 31, 2023 | -351.87% |